Literature DB >> 6758382

Carnitine in human nutrition.

A C Bach.   

Abstract

The oxidation of long-chain fatty acids is carnitine-dependent. Indeed, only when they are bound to carnitine, in the form of acyl-carnitines, do fatty acids penetrate into the mitochondria to be oxidized. To meet the need for carnitine, animals depend on both endogenous synthesis and an exogenous supply. A diet rich in meat supplies a lot of carnitine, while vegetables, fruits, and grains furnish relatively little. Although it has a low molecular weight and acts at low doses in a vital metabolic pathway, carnitine should not be considered a vitamin, but rather a nutritive substance. Indeed, it seems that the diet of the adult human need not necessarily furnish carnitine: the healthy organism, given a balanced nutrition (sufficiently rich in lysine and methionine), may well be able to meet all its needs. Furthermore, it seems that a reduction of the exogenous supply of carnitine results in a lowering of its elimination in the urine. However, dietary carnitine is more important during the neonatal period. The transition from fetal to extrauterine life is accompanied by an increased role of lipids in meeting energy needs. This change is accompanied by a rise in the body of the levels of carnitine, which is mainly supplied in the maternal milk. Finally, this review briefly surveys the illnesses in which a dietary carnitine supplement proves useful.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6758382     DOI: 10.1007/bf02020743

Source DB:  PubMed          Journal:  Z Ernahrungswiss        ISSN: 0044-264X


  62 in total

1.  An investigation of suggested physiological functions of carnitine.

Authors:  A E BENDER; E P ADAMS
Journal:  Biochem J       Date:  1962-02       Impact factor: 3.857

2.  [Clinical and humoral action of carnitine in the syndromes of post-infectious malnutrition in infancy].

Authors:  P BORNICHE; P CANLORBE
Journal:  Clin Chim Acta       Date:  1960-03       Impact factor: 3.786

3.  Carnitine.

Authors:  G FRAENKEL; S FRIEDMAN
Journal:  Vitam Horm       Date:  1957       Impact factor: 3.421

4.  Lilly Lecture 1978. New perspectives in the regulation of ketogenesis.

Authors:  J D McGarry
Journal:  Diabetes       Date:  1979-05       Impact factor: 9.461

5.  Some aspects of carnitine nutriture.

Authors:  H P Broquist; P R Borum
Journal:  Compr Ther       Date:  1977-10

6.  Dietary lysine and carnitine: relation to growth and fatty livers in rats.

Authors:  V Tanphaichitr; M S Zaklama; H P Broquist
Journal:  J Nutr       Date:  1976-01       Impact factor: 4.798

7.  Fatal cases of lipid storage myopathy with carnitine deficiency.

Authors:  F Cornelio; S Di Donato; D Peluchetti; A Bizze; B Bertagnolio; A D'Angelo; U Wiesmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-02       Impact factor: 10.154

8.  [Catabolism of carnitine: products of carnitine decarboxylase and carnitine dehydrogenase in vivo].

Authors:  H Seim; H Löster; E Strack
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1980-09

9.  Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia.

Authors:  M Maebashi; N Kawamura; M Sato; A Imamura; K Yoshinaga
Journal:  Lancet       Date:  1978-10-14       Impact factor: 79.321

10.  Relationships between carnitine and coenzyme A esters in tissues of normal and alloxan-diabetic sheep.

Authors:  A M Snoswell; P P Koundakjian
Journal:  Biochem J       Date:  1972-03       Impact factor: 3.857

View more
  3 in total

1.  Abnormally low serum acylcarnitine levels in narcolepsy patients.

Authors:  Taku Miyagawa; Hiroko Miyadera; Susumu Tanaka; Minae Kawashima; Mihoko Shimada; Yutaka Honda; Katsushi Tokunaga; Makoto Honda
Journal:  Sleep       Date:  2011-03-01       Impact factor: 5.849

Review 2.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

3.  Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis.

Authors:  Elizabeth J Meiman; Grace Robinson Kick; Cheryl A Jensen; Joan R Coates; Martin L Katz
Journal:  Dev Neurobiol       Date:  2022-04-28       Impact factor: 3.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.